(The 3rd CIIE) Pharmaceutical companies from various countries will go to the "Oriental Pact" at the CIIE
China News Service, November 10 (Reporter Zhang Hengwei and Li Jiajia) The third China International Import Expo is being held in Shanghai.
In the context of the severe impact of the new crown pneumonia epidemic on the global economy, the third CIIE will allow pharmaceutical companies from all over the world to go to the "Oriental Pact" again, conveying the message of "openness, cooperation, unity, and win-win".
According to reports, the medical equipment and medicines and health products exhibition area of this CIIE brought together more than 300 high-quality companies to participate in the exhibition, of which more than 70 are the world’s top 500 and leading companies in the industry, ranking top 10 in the global pharmaceutical industry and ranking in the medical device industry The top 14 companies all appeared here, bringing many new products, new technologies and new solutions.
One of the largest exhibitors in the medical equipment and health care exhibition area, Abbott, who participated in the CIIE for the first time, concentrated on exhibiting solutions to China’s increasingly severe major public safety and health issues in recent years, including its mobile Internet, precision, and minimally invasive solutions. Leading technology in cutting-edge medical trends.
It is understood that among the more than 100 exhibits on display by Abbott, nearly four of them have become the first shows in China, and there are even many world firsts.
For example, the new generation of disposable magneto-electric positioning pressure monitoring ablation catheter (referred to as: TactiCathSE ablation catheter) officially unveiled in China for the first time represents the world's most cutting-edge technology.
It relies on the accuracy of the magneto-electric dual positioning and the easy maneuverability to help improve the success rate of radiofrequency ablation surgery, the safety of the surgical process, and the doctor's intraoperative manipulation experience.
Ailand customizes personalized nutrition packs for users.
Photo by Zhang Hengwei
This time, Abbott’s total exhibition area is over 600 square meters, with more than 100 exhibits, including “one-stop solutions” and “black technologies” for major public diseases such as cardiovascular and diabetes, covering the entire life cycle of human beings. Scientific nutritional products, innovative diagnostic systems that help medical institutions improve their performance, respond to various inspection challenges, and high-quality, reasonably priced, and reliable drugs.
In the "Public Health Epidemic Prevention" zone, Abbott also demonstrated several new coronavirus tests including rapid test technology in China for the first time.
Carreno, vice president of Abbott’s nutrition business in North Asia, said in an interview that the scale of the CIIE continues to expand and its influence is increasing.
This year is the right time for Abbott. The first participation in this year further demonstrates Abbott’s long-term commitment to serve the Chinese market.
During the exhibition, Abbott also signed contracts with a number of provincial procurements, and reached a number of health strategic cooperation agreements with industry partners, covering the fields of medical equipment, nutrition, drugs, and diagnosis.
Among them, the diabetes business will continue the in-depth cooperation with Sinopharm, and the pharmaceutical business will also cooperate with a number of Internet medicine and innovative channel platforms such as JD Health, Keyuan Trading, Qingdao Baiyang, and Yiyao.com.
The exhibition area of Ailand Health Holdings Co., Ltd., which has participated in the CIIE for three consecutive years, is crowded with people. Advanced health management concepts, rich and innovative dosage experience, and diverse consumption scenarios present a new trend of personalized customized nutrition.
"This year is the third time that Aland has participated in the CIIE. The theme of the exhibition is to make individual nutrition possible." Chang Liang, chairman of Aland, introduced to reporters, as the nutrition and health products industry entered the "first half of marketing" In the second half of R&D, targeting the precise needs of subdivided groups has become the key.
Ailand is committed to becoming the world's leading service provider of nutrition and health solutions, and through the reshaping of the entire industry value chain from health needs assessment to customized solutions, to help the precise implementation of personalized nutrition.
GSK Consumer Health Products presented its latest innovative research results in the Chinese market at the CIIE.
Photo courtesy of GSK Consumer Health Products
“At present, most consumers do not understand their nutritional needs, and it is difficult to achieve the desired nutritional intake effect.” Dr. Yang Jitao, general manager of Oufei Gene said, genetic testing technology can provide data support for personalized health solutions, how to supplement nutrition, The number of supplements is determined by the data.
After last year, GlaxoSmithKline (GSK) Consumer Health Products participated in the exhibition again, bringing its latest innovative research results in the Chinese market to the CIIE, including about 70 products and 4 innovative health management self-test tools.
According to reports, GSK's booth area at this CIIE is larger than last year, covering an area of 800 square meters. Many innovative products on display are developed or introduced based on insights into Chinese consumers.
In addition to new products, GSK Consumer Health Products also showcased four innovative health management self-test tools to the public, including the "Shinda Smart Sensitivity Test" that can help consumers understand the health of their gums anytime and anywhere; they can check their physical condition at any time , "Voltarin Smart Posture Test Mini Program" for understanding pain risk and related knowledge; "Dietary Nutrition Self-test Tool" jointly developed with the Chinese Nutrition Society and providing dietary advice and nutritional guidance; and helping consumers pay attention to bone density issues "1 minute osteoporosis risk test".
The world's leading optics company Essilor Group made its third appearance at the CIIE this year. At its booth in the medical equipment and medicine and healthcare exhibition area, the new "cross-age" product-Xingqu Control Lenses made the world premiere.
Myopia has become a worldwide health crisis. It is estimated that by 2050, the global myopia population will exceed 5 billion.
According to data recently disclosed by the Ministry of Education, compared with the end of 2019, the myopia rate of students in the first half of this year has increased by 11.7%.
While reducing the clarity of the visual field, high myopia may also lead to various eye diseases, such as glaucoma, cataracts, retinal detachment and macular degeneration, which in turn brings the risk of blindness.
As Essilor’s new technology and smart device, Xingqu control lenses are designed with Essilor’s exclusive innovative HALT high aspheric microlens technology. By slowing down the development of myopia, it may effectively reduce the risk of blindness caused by high myopia.
Since 2018, Essilor has cooperated with the School of Ophthalmology and Optometry of Wenzhou Medical University in China to carry out a three-year clinical trial involving 167 children with myopia.
The experimental results of the first year showed that the average level of myopia development in children wearing Xingqu control lenses was reduced by more than 60% compared with children wearing single vision lenses.
The Carl Zeiss Group, which has a long history in the field of optics and optoelectronics, also demonstrated its innovative R&D and production in the field of epidemic prevention products at the CIIE this year.
For example, Zeiss Germany designed a breathing shield to protect ophthalmologists and patients, optimized and accelerated production in China, and successfully supported global customers during the epidemic, realizing Zeiss's concept of "in China, for the world".
During the CIIE, Zeiss launched the world's first Zeiss defensive lens capable of inactivating viruses. This is the first time that virus inactivation technology has been applied to optical lenses used by consumers. This innovative achievement has attracted widespread attention from customers at home and abroad.
Today, China has become one of Zeiss's largest and most important markets in the world.
As the only large-scale international exhibition confirmed to be held in the world in the second half of this year, continuous participation in the CIIE is an important manifestation of Zeiss's long-term commitment to the Chinese market.